Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of clinical trait–related small RNA biomarkers with weighted gene co-expression network analysis for personalized medicine in endocervical adenocarcinoma

ABSTRACT: Identification of clinical trait–related small RNA biomarkers with weighted gene co-expression network analysis for personalized medicine in endocervical adenocarcinoma

PROVIDER: PRJNA736733 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14783112.fastq.gz	Fastqsanger.gz
	SRR14783113.fastq.gz	Fastqsanger.gz
	SRR14783114.fastq.gz	Fastqsanger.gz
	SRR14783115.fastq.gz	Fastqsanger.gz
	SRR14783116.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

Identification of clinical trait–related small RNA biomarkers with weighted gene co-expression network analysis for personalized medicine in endocervical adenocarcinoma

Project description:Endocervical adenocarcinoma (EAC) is an uncommon aggressive type of endocervical adenocarcinoma that is not associated with human papillomavirus (HPV). At present, molecular research on EAC mainly focuses on the genome and mRNA transcriptome, the investigation of small RNAs in EAC has not been fully described. Here, we systematically explored small RNAs in 14 different subtypes of EAC using small RNA sequencing. miRNAs and tRNA-derived RNAs (tDRs) accounted for the majority of mapped reads the total number of miRNAs and tDRs maintained a relative balance. To explore the correlations between small RNAs and EAC with different clinical characteristics, we performed the weighted gene co-expression network analysis (WGCNA) and screened for hub small RNAs. From the key modules, we identified 9 small RNAs that were significantly related to clinical characteristics in EAC patients. Gene Ontology and pathway analyses revealed that these molecules could have roles in the pathogenesis of EAC. Our work provides new insight into EAC pathogenesis, and identify small RNAs as candidate biomarkers for diagnosis and prognosis of EAC.

2021-06-11 | GSE176579 | GEO

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

Project description:IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

| PRJNA606620 | ENA

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

Project description:IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

| PRJNA606621 | ENA

Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine

Project description:This SuperSeries is composed of the following subset Series: GSE29996: Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine [Affymetrix SNP array data] GSE29998: Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine [Illumina mRNA expression array data] Refer to individual Series

2012-10-25 | E-GEOD-29999 | biostudies-arrayexpress

Patient-Derived Models of Prostate Cancer for Personalized Medicine

Project description:Patient-Derived Models of Prostate Cancer for Personalized Medicine

| PRJNA1018661 | ENA

Reprograming human fibroblasts into Sertoli cells: a tool for personalized medicine

Project description:Reprograming human fibroblasts into Sertoli cells: a tool for personalized medicine

| PRJNA1032086 | ENA

PAGE: The Charles Bronfman Institute for Personalized Medicine (IPM) BioMe Biobank

Project description:PAGE: The Charles Bronfman Institute for Personalized Medicine (IPM) BioMe Biobank

| PRJNA285518 | ENA

Identification of clinical trait-related small RNA biomarkers with weighted gene co-expression network analysis for personalized medicine in endocervical adenocarcinoma.

Project description:Endocervical adenocarcinoma (EAC) is an aggressive type of endocervical cancer. At present, molecular research on EAC mainly focuses on the genome and mRNA transcriptome, the investigation of small RNAs in EAC has not been fully described. Here, we systematically explored small RNAs in 14 EAC patients with different subtypes using small RNA sequencing. MiRNAs and tRNA-derived RNAs (tDRs) accounted for the majority of mapped reads and the total number of miRNAs and tDRs maintained a relative balance. To explore the correlations between small RNAs expression and EAC with different clinical characteristics, we performed the weighted gene co-expression network analysis (WGCNA) and screened for hub small RNAs. From the key modules, we identified 9 small RNAs that were significantly related to clinical characteristics in EAC patients. Gene ontology and pathway analyses revealed that these molecules were involved in the pathogenesis of EAC. Our work provided new insights into EAC pathogenesis and successfully identified several small RNAs as candidate biomarkers for diagnosis and prognosis of EAC.

| S-EPMC8507262 | biostudies-literature

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [MethArray_5days]

Project description:The heterogenous genomic nature of most sarcoma subtypes makes them especially indicated for personalized treatment approaches. Here, we developed a personalized medicine strategy based in the use of patient-derived cell lines as a drug-testing platform. Targeted sequencing of a panel of cancer-related genes in these models revealed the presence of IDH1 and IDH2 mutations in two chondrosarcomas. Mutant IDH (mIDH) enzymes produce the oncometabolite 2-HG which contributes to driving tumor growth. Thus, we treated several chondrosarcoma models with specific mIDH1/2 inhibitors. Among these treatments, only the mIDH2 inhibitor enasidenib was able to decrease 2-HG levels and to efficiently reduce the viability of mIDH2 chondrosarcoma cells. Importantly, oral administration of enasidenib in xenografted mice resulted in a complete abrogation of tumor growth. Enasidenib induced a profound remodeling of the transcriptomic landscape not associated to changes in the 5mC methylation levels and its anti-tumor effects were associated to the repression of proliferative pathways such as those controlled by E2F factors. Overall, this work provides the first preclinical evidence for the use of enasidenib to treat mIDH2 chondrosarcomas.

2024-03-12 | GSE261421 | GEO

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [RNAseq_Enasidenib_L2975_SW1353]

2024-03-13 | GSE261434 | GEO